Hirotsugu Miyoshi

Dr. Hirotsugu Miyoshi

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
TWTomoyuki Watanabe
Tomoyuki Watanabe
KKKenshiro Kido
Kenshiro Kido
SKSatoshi Kamiya
Satoshi Kamiya
SOSachiko Otsuki
Sachiko Otsuki
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Introduction. We compared the hemodynamics during general anesthesia with remimazolam and conventional anesthetics in patients with severe aortic stenosis (AS). Methods. This was a retrospective single‐center analysis. We reviewed the records of 42 patients who underwent transcatheter aortic valve implantation with a transfemoral artery approach under general anesthesia from January to December 2020. Patients were divided into three groups based on the general anesthetic used for (induction/maintenance) remimazolam/remimazolam (Group R/R), propofol/sevoflurane (Group P/S), and midazolam/propofol (Group M/P). Vasopressor use (ephedrine, phenylephrine, and noradrenaline) was compared among the groups. Results. The number of patients in each group was 15 (Group R/R), 13 (Group P/S), and 14 (Group M/P), with no significant difference in background characteristics and intraoperative vital signs. For anesthesia induction, doses of ephedrine and phenylephrine used were significantly lower in Group R/R (ephedrine [mg]: Group R/R 2 [0–4] vs. Group P/S 8 [8–12], P < 0.001, Group R/R vs. Group M/P 5 [0–15], P = 0.39; phenylephrine (mg): Group R/R 0 [0–0.08] vs. Group P/S 0.15 [0.10–0.20], P = 0.03, Group M/P 0.21 [0.04–0.40], P = 0.08). For anesthesia maintenance, the noradrenaline dose used was low in the Group R/R (noradrenaline [μg/kg/min]: Group R/R 0.019 [0.015–0.039], Group P/S 0.042 [0.035–0.045], P = 0.02, Group M/P 0.048 [0.040–0.059], P < 0.01). Conclusion. In patients with severe AS, induction and maintenance of anesthesia with remimazolam resulted in less overall vasopressor use than conventional general anesthetics.

9 December 2020 in JA Clinical Reports
Verified
Journal Article
Open access
PDF file
TKTakashi Kondo
Takashi Kondo
YTYukari Toyota
Yukari Toyota
SNSoshi Narasaki
Soshi Narasaki
TWTomoyuki Watanabe
Tomoyuki Watanabe
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Background: Remimazolam is a novel short-acting benzodiazepine characterized by metabolism independent from organ function. We report intraoperative MEP responses of two patients who underwent spine surgery under general anesthesia using remimazolam.Case presentation: In case 1, MEP monitoring was successfully performed with the use of a fixed dose of remimazolam at 0.5 mg/kg/h and remifentanil at 0.2 μg/kg/min. In case 2, an increasing dose of remimazolam from 0.5 to 1.5 mg/kg/h during the operation did not affect MEP signals. In both cases, remimazolam was titrated to maintain the values of entropy electroencephalogram (EEG) monitoring at 40–60.Conclusions: General anesthesia using remimazolam and remifentanil can be a valuable alternative for spine surgery with MEP monitoring by EEG to assess the optimal dose.

1 September 2021 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
AMAtsushi Morio
Atsushi Morio
RTRie Tsutsumi
Rie Tsutsumi
TKTakashi Kondo
Takashi Kondo
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
TKTakahiro Kato
Takahiro Kato
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi

4 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
TWTomoyuki Watanabe
Tomoyuki Watanabe
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
YNYuko Noda
Yuko Noda
SNSoshi Narasaki
Soshi Narasaki
AMAtsushi Morio
Atsushi Morio
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
Background. We investigated the potential safety of remimazolam and propofol in malignant hyperthermia‐ (HM‐) susceptible patients using ryanodine receptor 1‐ (RYR1‐) expressing human embryonic kidney‐ (HEK‐) 293 cells. Methods. We compared the enhanced responsiveness of HEK‐293 cells expressing wild‐type RYR1 with that of mutant RYR1 to caffeine following perfusion with remimazolam or propofol. Furthermore, we investigated whether RYR1 enhanced the responsiveness of cells to remimazolam or propofol and compared the median effective concentration (EC50; i.e., the concentration required to reach half‐maximal activation) using an unpaired two‐tailed t‐test while a P < 0.05 was considered significant. Results. Remimazolam and propofol did not promote the caffeine‐induced increase in intracellular Ca2+ levels in HEK‐293 cells expressing mutant RYR1 even with exposure to approximately 100‐fold the clinically used concentration. In wild‐type RYR1, EC50 values of remimazolam following refusion vs. nonperfusion were 2.86 mM vs. 2.75 mM (P = 0.76) while for propofol perfusion vs. nonperfusion, they were 2.76 mM vs. 2.75 mM, respectively (P = 0.83). In mutant RYR1, EC50 values of remimazolam refusion vs. nonperfusion were 1.58 mM vs. 1.71 mM, respectively (P = 0.63) while for propofol perfusion vs. nonperfusion, they were 1.65 mM vs. 1.71 mM, respectively (P = 0.73). Remimazolam and propofol increased intracellular Ca2+ levels in a concentration‐dependent manner, but the effect was not enhanced by RYR1. EC50 values of remimazolam with non‐RYR1 vs. wild‐type RYR1 were 1.00 mM vs. 0.92 mM, respectively (P = 0.91) while those of propofol were 1.09 mM vs. 1.05 mM, respectively (P = 0.84). Conclusions. The increase in intracellular Ca2+ concentration caused by remimazolam or propofol was not considered an RYR1‐mediated reaction. We conclude that remimazolam and propofol can be safely used as an anesthetic in MH‐susceptible patients with RYR1‐mutation without causing MH and may be safely substituted for an MH‐triggering anesthetic when RYR1‐mediated MH occurs.

20 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AMAyumu Matsumoto
Ayumu Matsumoto
SSShiho Satomi
Shiho Satomi
NKNami Kakuta
Nami Kakuta
SNSoshi Narasaki
Soshi Narasaki
YTYukari Toyota
Yukari Toyota
Yasuo TsutsumiYasuo Tsutsumi
Yasuo Tsutsumi
(1) Background: Remimazolam is a novel benzodiazepine that prevents postoperative nausea and vomiting (PONV), is more effective than volatile anesthetics, and was recently approved for use in Japan. (2) Methods: This prospective, double-blind, randomized controlled trial study aimed to compare the efficacy of remimazolam and propofol as general anesthetics in terms of the incidence of PONV after laparoscopic gynecological surgery (UMIN000046237). High-risk female patients who underwent general anesthesia with either remimazolam or propofol for the maintenance of anesthesia were enrolled. The primary outcome was the incidence of PONV in the two groups (i.e., REM versus PROP) 2 h and 24 h after surgery. The incidence of vomiting without nausea, rescue antiemetic use, and the severity of nausea were also evaluated. (3) Results: No significant differences in PONV were identified between the REM and PROP groups at 2 h or 24 h. Furthermore, no differences were observed in any of the measured parameters, and no adverse events were reported. (4) Conclusions: The results of the present study suggest that remimazolam may be as effective as propofol in preventing PONV; however, further investigation is necessary to identify possible differences between these two agents.

1 February 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TUTomoaki Urabe
Tomoaki Urabe
HMHirotsugu Miyoshi
Hirotsugu Miyoshi
SNSoshi Narasaki
Soshi Narasaki
YYYuhki Yanase
Yuhki Yanase
KUKazue Uchida
Kazue Uchida
NSNorio Sakai
Norio Sakai
Many anesthetics, including Propofol, have been reported to induce elevation of intracellular calcium, and we were interested to investigate the possible contribution of calcium elevation to the mechanism of the newly approved remimazolam actions. Remimazolam is an intravenous anesthetic first approved in Japan in July 2020, and is thought to exert its anesthetic actions via γ-aminobutyric acid A (GABAA) receptors; however, the precise mechanisms of how remimazolam elevates intracellular calcium levels remains unclear. We examined the remimazolam-induced elevation of intracellular calcium using SHSY-5Y neuroblastoma cells, COS-7 cells, HEK293 cells, HeLa cells, and human umbilical vein endothelial cells (HUVECs) loaded with fluorescent dyes for live imaging. We confirmed that high concentrations of remimazolam (greater than 300 μM) elevated intracellular calcium in a dose-dependent manner in these cells tested. This phenomenon was not influenced by elimination of extracellular calcium. The calcium elevation was abolished when intracellular or intraendoplasmic reticulum (ER) calcium was depleted by BAPTA-AM or thapsigargin, respectively, suggesting that calcium was mobilized from the ER. Inhibitors of G-protein coupled receptors (GPCRs)-mediated signals, including U-73122, a phospholipase C (PLC) inhibitor and xestospongin C, an inositol 1,4,5-triphosphate receptors (IP3R) antagonist, significantly suppressed remimazolam-induced calcium elevation, whereas dantrolene, a ryanodine receptor antagonist, did not influence remimazolam-induced calcium elevation. Meanwhile, live imaging of ER during remimazolam stimulation using ER-tracker showed no morphological changes. These results suggest that high doses of remimazolam increased intracellular calcium concentration in a dose-dependent manner in each cell tested, which was predicted to be caused by calcium mobilization from the ER. In addition, our studies using various inhibitors revealed that this calcium elevation might be mediated by the GPCRs-IP3 pathway. However, further studies are required to identify which type of GPCRs is involved.